ACON

Aclarion, Inc. (ACON) | Rumor.io

Aclarion

ACON

Attention (50-day avg)0%

Attention rank (50-day avg)#3,892

Bullish sentiment (50-day avg)75%

Price to earnings ratio-0.18

Market capitalization7M

Earnings per share-6.96

Dividend yield (TTM)163.9%

Revenue (annual)75.7K

Net income (annual)-7.2M

Social

What share of all stock conversation is about ACON?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% -0.01

May 28

Aclarion, Inc. (ACON) has received a buyout offer from Echo Lake Capital.
The offer is valued at $4 per share, with a cash value of $6 per share, and has been made by the company's largest shareholder.
ACON's stock price has been volatile in pre-market trading, with some investors expressing optimism about the potential acquisition.

Generated by AI

Sentiment

Of the messages about ACON that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% new	75% -8.33	80.99% +2.28
Bearish	—	0% -100	25% +8.33	19.01% -2.28

Bullish· Jan 9

The company has a strong cash position, with $22 million in cash and 2.8 million shares outstanding, translating to $7.85 per share.
The recent operational numbers show significant growth, with revenue increasing to $8.01 million and volumes hitting 2.53 million gallons, indicating a strong service monetization and logistics execution.
The company's AI component is expected to be further enhanced, which is a hot trend, and the shares are expected to rally to $10, with some analysts predicting a price target of $20.

Bearish· Jan 13

The company has been accused of running a ponzi scheme, with some investors claiming they stole $12,000,000 by selling shares after revealing they had $12,000,000 in cash and zero debt.
The company's decision to sell shares and raise $12,000,000 has been criticized as unnecessary, with some accusing them of manipulating the stock price to benefit from the offering.
The company's management, including Robert Dawson, have been called out for their actions, with some calling for their licenses to be revoked and for them to face jail time.

Generated by AI

Topics

Of the messages about ACON that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	25%	58%
Technical Analysis	—	100%	75%	32.52%
Analysts	—	0%	0%	1.49%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	8%

Announcements· Jan 8

$ACON announced a 69% year-over-year increase in Nociscan scan volumes in 2025, with a 114% increase in Q4.
The company has a cash runway into the first half of 2027, with $12 million in cash and no debt, and is expected to achieve a major breakthrough soon.
Aclarion's Nociscan platform is rapidly penetrating a large potential market, supported by progress in key clinical trials and sound financials.

Technical Analysis· Jan 8

The chart for $ACON is showing a potential breakout, with a bounce off the $7.00 pivot zone and a test of pre-market highs at $9.36.
The stock is holding the 7.80–8.00 area well, and needs to go over VWAP around 8.30–8.35 with volume to trigger the next leg.
$ACON is showing high relative strength, and is being set up for a potential multi-day runner, with a chart that looks great and is breaking out in the afternoon.

Generated by AI

Community

Of the messages about ACON, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	42.86%	36.36%	45.84%
Newcomers	—	57.14%	63.64%	54.16%

Regulars· Jan 9

The $ACON stock price has experienced a significant sell-off, with 24k shares sold off, and is now looking for support at $4.92.
The company, Aclarion, Inc., has filed an 8-K report announcing a stock offering, selling 200,000 shares at $5.18 each and pre-funded warrants to purchase up to 1,800,000 shares.
The regulars are nostalgic for the "old days" of trading, when stocks traded more freely, and are frustrated with the current range-bound and unpredictable market conditions.

Newcomers· Jan 9

Aclarion, Inc. ($ACON) has seen a 75% price explosion in one week, sparking questions about whether this is the start of a long-term bull run or a short-term spike.
The stock is extremely thin, with a wide spread between the bid and ask prices, indicating a lack of liquidity and potential for significant price movements.
Aclarion's CEO has taken a huge dump on shareholders, with the stock experiencing a significant decline in value, and many are speculating about the company's financial health and clinical progress.

Generated by AI

University of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic spine program with deep expertise in complex spine surgery and a strong commitment to clinical research and innovationTen sites now actively enrolling in CLARITY study, a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan® aims to become the gold standard in identifying sources of low back pain through

1mo agoYahoo Finance

Also Discussed

Investors talking about ACON also mention

#	Name	Attention
1	GlucoTrack Inc.GCTK	0%0
2	NewGenIvf Group Limited Class A Ordinary SharesNIVF	0%0
3	Crown Electrokinetics Corp.CRKN	0%0
4	Jet.AI Inc.JTAI	0%new
5	Sharps Technology Inc.STSS	0%0
6	N2OFF, Inc.NITO	0%0
7	Ocean Biomedical Inc.OCEA	0%0
8	MicroAlgo Inc.MLGO	0%new
9	CNS Pharmaceuticals Inc.CNSP	0%0
10	Newton Golf Company Inc.SPGC	0%new

Aclarion, Inc.

Healthcare
Health Information Services

Aclarion, Inc. is a healthcare technology company focused on using magnetic resonance spectroscopy and proprietary signal-processing biomarkers to support the evaluation of spine-related pain. Its core product, Nociscan, is a cloud-based software platform designed to help physicians analyze intervertebral disc chemistry and identify discs associated with chronic low back pain. The company’s solutions combine imaging data, augmented intelligence, and clinical decision-support tools to improve how specialists assess pain sources and plan treatment. Aclarion serves the medical imaging and spine care markets, with current offerings centered on noninvasive diagnostics and software-based analysis for healthcare providers. Headquartered in Broomfield, Colorado, Aclarion operates at the intersection of diagnostic imaging, health information services, and precision pain assessment.

Website

Location

8181 Arista Place

Broomfield, CO, 80021

United States

Social

What share of all stock conversation is about ACON?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% -0.01

May 28

Aclarion, Inc. (ACON) has received a buyout offer from Echo Lake Capital.
The offer is valued at $4 per share, with a cash value of $6 per share, and has been made by the company's largest shareholder.
ACON's stock price has been volatile in pre-market trading, with some investors expressing optimism about the potential acquisition.

Generated by AI

Sentiment

Of the messages about ACON that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% new	75% -8.33	80.99% +2.28
Bearish	—	0% -100	25% +8.33	19.01% -2.28

Bullish· Jan 9

The company has a strong cash position, with $22 million in cash and 2.8 million shares outstanding, translating to $7.85 per share.
The recent operational numbers show significant growth, with revenue increasing to $8.01 million and volumes hitting 2.53 million gallons, indicating a strong service monetization and logistics execution.
The company's AI component is expected to be further enhanced, which is a hot trend, and the shares are expected to rally to $10, with some analysts predicting a price target of $20.

Bearish· Jan 13

The company has been accused of running a ponzi scheme, with some investors claiming they stole $12,000,000 by selling shares after revealing they had $12,000,000 in cash and zero debt.
The company's decision to sell shares and raise $12,000,000 has been criticized as unnecessary, with some accusing them of manipulating the stock price to benefit from the offering.
The company's management, including Robert Dawson, have been called out for their actions, with some calling for their licenses to be revoked and for them to face jail time.

Generated by AI

Topics

Of the messages about ACON that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	25%	58%
Technical Analysis	—	100%	75%	32.52%
Analysts	—	0%	0%	1.49%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	8%

Announcements· Jan 8

$ACON announced a 69% year-over-year increase in Nociscan scan volumes in 2025, with a 114% increase in Q4.
The company has a cash runway into the first half of 2027, with $12 million in cash and no debt, and is expected to achieve a major breakthrough soon.
Aclarion's Nociscan platform is rapidly penetrating a large potential market, supported by progress in key clinical trials and sound financials.

Technical Analysis· Jan 8

The chart for $ACON is showing a potential breakout, with a bounce off the $7.00 pivot zone and a test of pre-market highs at $9.36.
The stock is holding the 7.80–8.00 area well, and needs to go over VWAP around 8.30–8.35 with volume to trigger the next leg.
$ACON is showing high relative strength, and is being set up for a potential multi-day runner, with a chart that looks great and is breaking out in the afternoon.

Generated by AI

Community

Of the messages about ACON, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	42.86%	36.36%	45.84%
Newcomers	—	57.14%	63.64%	54.16%

Regulars· Jan 9

The $ACON stock price has experienced a significant sell-off, with 24k shares sold off, and is now looking for support at $4.92.
The company, Aclarion, Inc., has filed an 8-K report announcing a stock offering, selling 200,000 shares at $5.18 each and pre-funded warrants to purchase up to 1,800,000 shares.
The regulars are nostalgic for the "old days" of trading, when stocks traded more freely, and are frustrated with the current range-bound and unpredictable market conditions.

Newcomers· Jan 9

Aclarion, Inc. ($ACON) has seen a 75% price explosion in one week, sparking questions about whether this is the start of a long-term bull run or a short-term spike.
The stock is extremely thin, with a wide spread between the bid and ask prices, indicating a lack of liquidity and potential for significant price movements.
Aclarion's CEO has taken a huge dump on shareholders, with the stock experiencing a significant decline in value, and many are speculating about the company's financial health and clinical progress.

Generated by AI

Aclarion

Social

May 28

Bullish· Jan 9

Bearish· Jan 13

Announcements· Jan 8

Technical Analysis· Jan 8

Regulars· Jan 9

Newcomers· Jan 9

Aclarion adds University of Arizona to Nociscan spine trial

Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site

Aclarion director Amanda Williams buys $15,989 in common stock

Aclarion CFO Gregory Gould buys $24,500 of Aclarion stock

Aclarion CEO Brent Ness buys $12,090 in company stock

Aclarion director David K. Neal buys $18,000 in common stock

Also Discussed

Aclarion, Inc.

Company Information

Location

Aclarion adds University of Arizona to Nociscan spine trial

Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site

Aclarion director Amanda Williams buys $15,989 in common stock

Aclarion CFO Gregory Gould buys $24,500 of Aclarion stock

Aclarion CEO Brent Ness buys $12,090 in company stock

Aclarion director David K. Neal buys $18,000 in common stock

Also Discussed

Social

May 28

Bullish· Jan 9

Bearish· Jan 13

Announcements· Jan 8

Technical Analysis· Jan 8

Regulars· Jan 9

Newcomers· Jan 9